MORRIS PLAINS, N.J., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that Michael Pehl, President and Chief Executive Officer, will participate in the following healthcare conferences:
B. Riley FBR Healthcare Conference in a panel discussion titled, “Antibody-drug conjugates are a waning technology,” on Tuesday, September 4, 2018 at 12:50 p.m.at the New York Marriott East Side Hotel in New York, NY (webcast not available)
Baird 2018 Global Healthcare Conference on Wednesday, September 5, 2018 at 9:05 a.m. Eastern Time at The InterContinental New York Barclay Hotel in New York, NY (webcast available)
2018 Wells Fargo Healthcare Conference on Thursday, September 6, 2018 at 1:20 p.m. Eastern Time at The Westin Copley Place Hotel in Boston, MA (webcast available)
Morgan Stanley 16th Annual Global Healthcare Conference (fireside chat format) on Wednesday, September 12, 2018 at 4:15 pm Eastern Time at the Grand Hyatt Hotel in New York, NY (webcast available)
Live audio webcast will be accessible from the Company’s website at https://immunomedics.com/investors/. The Company will als participate in one-on-one meetings with institutional investors at these conferences.
About Immunomedics Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer and other serious diseases. Immunomedics’ corporate objective is to become a fully-integrated biopharmaceutical company and a leader in the field of antibody-drug conjugates. For additional information on the Company, please visit its website at https://immunomedics.com/. The information on its website does not, however, form a part of this press release.
Cautionary note regarding forward-looking statements This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials (including the funding therefor, anticipated patient enrollment, trial outcomes, timing or associated costs), regulatory applications and related timelines, including the filing and approval timelines for BLAs and BLA supplements, out-licensing arrangements, forecasts of future operating results, potential collaborations, capital raising activities, and the timing for bringing any product candidate to market, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, the Company’s dependence on business collaborations or availability of required financing from capital markets, or other sources on acceptable terms, if at all, in order to further develop our products and finance our operations, new product development (including clinical trials outcome and regulatory requirements/actions), the risk that we or any of our collaborators may be unable to secure regulatory approval of and market our drug candidates, risks associated with the outcome of pending litigation and competitive risks to marketed products, and the Company’s ability to repay its outstanding indebtedness, if and when required, as well as the risks discussed in the Company’s filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.
For More Information:
For Investor Inquiries: Dr. Chau Cheng Senior Director, Investor Relations & Corporate Secretary (973) 605-8200, extension 123 [email protected]
